Aller au contenu principal
Accès ouvert déclaré 2026 article

Impfungen bei Immunsuppression, Immundefekten und immunmodulierenden Therapien: Empfehlungen – Update 2026

0Citations signalées, ce qui n’est pas une note de qualité
11Institutions déclarées
2Pays d’affiliation déclarés

Rattachement africain : at, de. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Immunosuppression of various origins is associated with an increased risk of infections and infection-triggered morbidity and mortality. Vaccination, therefore, plays a central role in the care of immunosuppressed individuals by protecting against vaccine-preventable diseases.Based on the available evidence as well as immunological and theoretical considerations, an expert statement on vaccination in immunocompromised individuals was first formulated in 2016. These recommendations have herewith been comprehensively updated and expanded. The aim is to provide a practice-oriented, indication- and therapy-specific guidance document for clinical care. A practical chart accompanying the present vaccination recommendation, which also functions as a decision tree for implementation, facilitates orientation within the document.The document includes an introductory section outlining fundamental aspects of immunosuppression and addressing immunological and organizational issues relevant to vaccination planning, application, and control of vaccination responsiveness. In addition, current developments regarding relevant vaccines are reviewed.Subsequently, a systematic overview of immunosuppressive agents commonly used across medical specialties is provided. These agents are categorized according to their degree of immunosuppression and the associated infection risks. Standardized vaccination schedules are provided and assigned to the respective drug classes to facilitate a structured approach in clinical practice. The decision on vaccination eligibility of these patients can only be made based on a comprehensive assessment of the underlying disease and the planned or ongoing immunosuppressive therapy.Special clinical situations-including circumstances in which vaccination cannot be performed, as well as travel-related vaccinations in the context of immunosuppression-are addressed in separate chapters. To ensure long-term relevance, the document refers to continuously updated external sources throughout, which are compiled at the end.This document acts as general recommendation without a claim of completeness. The specific procedure in clinical practice can be adapted to the clinical context, and the reader is referred to the respective professional societies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Impfungen bei Immunsuppression, Immundefekten und immunmodulierenden Therapien: Empfehlungen – Update 2026 Vaccination of immunocompromised individuals: Expert opinion – update 2026
Date Crossref
01/07/2026
Éditeur
Springer Science and Business Media LLC
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Travel-related health issuesPediatric health and respiratory diseasesLymphadenopathy Diagnosis and Analysis

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.